Home
Conditions
Lymphoproliferative Disorders

Clinical trial condition

Lymphoproliferative Disorders

Explore clinical trials studying Lymphoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,144 public trials 2,036 recruiting studies

Refine in advanced search Browse all conditions

Lymphoproliferative Disorders trial results

Not yet recruiting

A Single-arm, Single-center, Open-label Phase II Study of Zanubrutinib Combined With R-CHOP/R-DHAP in Newly Diagnosed Mantle CellLymphoma Patients

NCT06255704

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations: Hematology Department of ShanXi Cancer Hospital Taiyuan, Shanxi, China

View Trial Details

Not yet recruiting

Coagulopathy in Childhood Acute Lymphoblastic Leukaemia

NCT06242353

Conditions: Acute Lymphoblastic Leukemia, Bleeding, Cardiovascular Diseases, +20 more
Locations: Not specified

View Trial Details

Not yet recruiting

Treatment Protocol for Newky Diagnosed Adult Ph Positive ALL

NCT06175702

Conditions: Adult ALL, Hematologic Diseases, Hemic and Lymphatic Diseases, +11 more
Locations: Not specified

View Trial Details

Not yet recruiting

Response Adapted Incorporation of Tislelizumab Into the Front-line Treatment of Older Patients With Hodgkin lYmphoma

NCT05627115

Conditions: Hemic and Lymphatic Diseases, Hodgkin Disease, Hodgkin Lymphoma, +7 more
Locations: Not specified

View Trial Details

Not yet recruiting

Study of SP-3164 in Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT05979857

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +6 more
Locations: Not specified

View Trial Details

Not yet recruiting

Relmacabtagene Autoleucel in Hematologic Malignancies

NCT06142188

Conditions: Follicular Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +10 more
Locations: Beijing Cancer Hospital Beijing, Beijing Municipality, China

Peking University International Hospital Beijing, Beijing Municipality, China

View Trial Details

Not yet recruiting

Selinexor Combined With R-GDP Regimen for TP53-altered R/R DLBCL

NCT06062641

Conditions: Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +13 more
Locations: Ruijin Hospital Shanghai, Shanhai, China

View Trial Details

Not yet recruiting

First in Human Study of the Infusion of ARI0003 Cells in Relapsed/Refractory to Treatment B-cell Aggressive Lymphoma

NCT06097455

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations: CHU Santiago de Compostela Santiago de Compostela, A Coruña, Spain

Hospital Clínic Barcelona Barcelona, Spain

H. Ramon y Cajal Madrid, Spain

H.U. Virgen de la Arrixaca Murcia, Spain

View Trial Details

Not yet recruiting

(CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL)

NCT05923502

Conditions: Chronic Disease, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Diffuse Large B Cell Lymphoma, +27 more
Locations: Not specified

View Trial Details

Not yet recruiting

Blinatumomab Prevents Recurrence of R/R ALL After Allo-HSCT

NCT06075238

Conditions: Hematologic Diseases, Hemic and Lymphatic Diseases, Immune System Diseases, +7 more
Locations: West China Hospital of Sichuan University Chengdu, Sichuan, China

View Trial Details

Lymphoproliferative Disorders

Lymphoproliferative Disorders trial results

Related conditions